Whereas the effect of AsA on other angiogenic factors remains unstudied, the results from our completed studies clearly indicate that AsA treatment could inhibit VEGF secretion by LN18 and U87-MG cells; thereby it could inhibit the pro-angiogenic effects of these glioma cells. This evidence concerns the gene VEGFA and central nervous system cancer.